Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Waldenstrom Macroglobulinemia Treatment Options: Alkylators Are Recommended for Primary Therapy, PFS Was Significantly Higher for Ibrutinib + Rituximab vs. Rituximab (iNNOVATE Trial)

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Joshua Richter
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Joshua Richter
307 views
November 19, 2019
1 Comment
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
Independent Satellite Symposium
15:53

CAR T-Cell Therapy for Multiple Myeloma: The Future of Myeloma Care?

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

S. Lonial

168 views
25:14

Waldenstrom Macroglobulinemia Treatment Options: Alkylators Are Reco…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

J. Richter

307 views
25:23

Current and Emerging Treatment Options in Waldenström Macroglobuline…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Dimopoulos

145 views